Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility
NCT00591851
Completed
HER-2/neu (+) breast cancer is a more aggressive form of breast cancer. HER-2/neu is a protein that is overproduced by your tumor. It makes your cancer more aggressive. Standard treatments for this type of cancer will help some people, but there is a moderate to high chance that your cancer may come back. The purpose of this study is to see if a new regimen will be effective in preventing cancer from coming back. This is a phase II trial. In this trial, patient get a drug regimen that has been... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/11/2023
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Breast Cancer
Register for Updates
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
NCT03611556
Completed
The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in participants with metastatic pancreatic cancer.
Gender:
ALL
Ages:
Between 18 years and 101 years
Trial Updated:
09/08/2023
Locations: Research Site, La Jolla, California +26 locations
Conditions: Carcinoma, Metastatic Pancreatic Adenocarcinoma
Register for Updates
A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus
NCT02744898
Completed
The purpose of this study is to evaluate the safety of treatment with carboplatin and Abraxane in this patient population and determine the nature and degree of toxicities following treatment. The single stage open label Phase II feasibility study is designed to estimate the proportion of patients who can tolerate the proposed regimen for 6 cycles with no more than two dose level reductions.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/31/2023
Locations: NYU Perlmutter Cancer Center, New York, New York
Conditions: Endometrial Cancer
Register for Updates
Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
NCT03910387
Active Not Recruiting
This phase II trial studies how well telotristat ethyl works in promoting weight stability in patients with pancreatic adenocarcinoma that has come back and spread to other places in the body. Telotristat ethyl may decrease bowel movements which may make patients gain weight. Stabilizing weight may help patients tolerate chemotherapy better and improve longevity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2023
Locations: Emory University Hospital Midtown, Atlanta, Georgia +2 locations
Conditions: Locally Advanced Unresectable Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Register for Updates
Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer
NCT02317874
Completed
This phase I trial studies the side effects and best dose of talazoparib when given together with carboplatin and paclitaxel in treating patients with solid tumors that have spread to other places in the body (advanced) or cannot be removed by surgery. Talazoparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of tar... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2023
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey +2 locations
Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Register for Updates
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
NCT04081389
Completed
This phase I trial studies how well chemokine modulation therapy and standard chemotherapy given before surgery work in treating patients with early stage triple negative breast cancer. Chemokine modulation therapy, including celecoxib, recombinant interferon alfa-2b, and rintatolimod, may stimulate the immune system and stop tumor cells from growing. Drugs used in standard chemotherapy, such as paclitaxel, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cel... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/25/2023
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Register for Updates
AO-176 in Multiple Solid Tumor Malignancies
NCT03834948
Completed
This is a first-in-human, Phase 1/2 multi-center, open-label, dose escalation and expansion study of AO-176 which will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and clinical effects of AO-176 in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2023
Locations: University of Southern California, Los Angeles, California +9 locations
Conditions: Solid Tumor
Register for Updates
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
NCT00934895
Terminated
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving paclitaxel albumin-stabilized nanoparticle formulation together with everolimus may kill more tumor cells. PURPOSE: This phase... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
08/21/2023
Locations: Cooper Hospital/University Medical Center, Camden, New Jersey +2 locations
Conditions: Breast Cancer
Register for Updates
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
NCT03329378
Terminated
Primary Objective: • Determination of pathologic complete response (pCR) rates Secondary Objective: * Determination of cardiac toxicity as measured by: composite of LVEF, longitudinal strain and troponin. * Breast conservation rates * Overall survival Study Design * Approximately 34-74 patients with Her2 positive, Stage II-regional IV breast cancer will be enrolled. * Patients will be stratified by ER/PR status. * They will be randomized to ddACTHP vs TCHP. * Initially, 17 patients will... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/18/2023
Locations: Mount Sinai Beth Israel, New York, New York +2 locations
Conditions: Locally Advanced Breast Cancer
Register for Updates
Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma
NCT01470417
Completed
This study will evaluate the role of Gemcitabine and Abraxane in the treatment of resectable and borderline-resectable pancreatic cancer by giving the chemotherapy before surgery.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
08/18/2023
Locations: University of Florida Shands Cancer Center, Gainesville, Florida
Conditions: Pancreatic Cancer
Register for Updates
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
NCT01196390
Completed
This randomized phase III trial studies how well radiation therapy, paclitaxel, and carboplatin with or without trastuzumab work in treating patients with esophageal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as trastuzumab,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2023
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +633 locations
Conditions: Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7, Stage IIA Esophageal Cancer AJCC v7, Stage IIB Esophageal Cancer AJCC v7, Stage IIIA Esophageal Cancer AJCC v7, Stage IIIB Esophageal Cancer AJCC v7
Register for Updates
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer
NCT01367301
Terminated
This pilot clinical trial studies radiation therapy, paclitaxel, and carboplatin in treating patients with uterine cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Giving radiation with chemotherapy may kill more tumor cells.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/15/2023
Locations: Albert Einstein College of Medicine, Bronx, New York
Conditions: Stage IA Uterine Sarcoma, Stage IB Uterine Sarcoma, Stage IC Uterine Sarcoma, Stage IIA Uterine Sarcoma, Stage IIB Uterine Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Carcinosarcoma
Register for Updates